Onco Actu du 28 janvier 2016

	1. Biologie
Cancer riddle, solved [University of Iowa] University of Iowa researchers have documented how cancerous tumors form by tracking in real time the movement of individual cells in 3-D. They report that just 5 percent of cancer cells are needed to form tumors, a ratio that heretofore had been unknown.
	3.1 Tabac
Australian teenage smoking at record low but 'constant vigilance' required [The Guardian] The latest New South Wales data showed 6.7% of adolescents in 2014 described themselves as heavy, light or occasional smokers compared with 23.5% in 1996.
Teens who try e-cigarettes more likely to start smoking [Reuters] The results from surveys following more than 2,300 high school students in Hawaii mirror findings from a separate analysis of smoking habits among about 2,500 Los Angeles teens published in JAMA last August, adding to evidence that using e-cigarettes may be a gateway to smoking tobacco.
	3.3 Prévention - Vaccins
HPV vaccination: A public health priority [ACS] Today, National Cancer Institute-designated Cancer Centers across the country issued a consensus statement urging action to increase vaccination against human papillomavirus (HPV).
	4.10 Dép., diag. & prono. - Poumon
Smokers Who Quit More Than 15 Years Ago Need Screening [Mayo Clinic] If confirmed, she recommends that policymakers consider changing the lung cancer screening guidelines to include people who quit smoking more than 15 years ago. She also recommends that policymakers continue to re-examine lung cancer screening criteria to account for changes in groups that are most at risk.
	5. Traitements
Faster drug discovery? [MIT News] Startup develops more cost-effective test for assessing how cells respond to chemicals.
Nivolumab Combined with Radiation Therapy May Be New Treatment Option for Patients with Melanoma Brain Metastases, Say Moffitt Cancer Center Researchers [Moffitt Cancer Center] The team retrospectively analyzed data from 26 patients who were treated with nivolumab and stereotactic radiotherapy. The patients had participated in two separate clinical trials at Moffitt.
	5.12 Immunothérapies
Kochenderfer: 'I think the main focus of the CAR field will be autologous cells...' [FierceBiotech] "If you mean use of 'off-the-shelf' non-HLA-matched donor cells, I tend to believe that use of autologous T cells is the best way to go. If the T cells are not HLA-matched, I think there will always be big problems with rejection of the T cells by the recipient's immune system."
	5.2 Pharma
Boehringer Ingelheim’s Giotrif® / Gilotrif® (afatinib) demonstrated superiority to Iressa® (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer [Boehringer Ingelheim] Results from the LUX-Lung 7 trial showed that afatinib significantly reduced the risk of lung cancer progression by 27% versus gefitinib.
Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy [AbbVie] The Breakthrough Therapy Designation is supported by data from untreated patients, 65 years or older with AML and reported in one investigational study.
Incyte stops tests on Jakafi to treat colorectal cancer [Reuters] The results cast a shadow on the prospects of the drug, Jakafi, which is also being studied in a late-stage trial to treat advanced pancreatic cancer.
	5.2.1 Pharma - Partenariats
Open access research partnership to 'crowdsource' new myeloma drugs [Pharmafile] Myeloma UK and the Structural Genomics Consortium (SGC) have entered into an open-access research partnership to find new drug targets for myeloma using structural biology and chemical proteomics.
CRT announces license agreement with MSD to develop inhibitors of PRMT5 for cancer and blood disorders [Cancer Research UK] The PRMT5 protein is involved in many cellular processes including the epigenetic control of genes such as p53 – a gene that protects the cell against cancer-causing mutations and is faulty in nine out of ten cancers.
	5.2.3 Pharma - économie
Langer-backed biotech reboots with $38M, new name and new cancer drug tech [FierceBiotech] Say goodbye to Blend Therapeutics and hello to Tarveda. The pipeline at Tarveda will concentrate on Pentarins, "miniaturized" biologic drug conjugates designed to get deeper into solid tumors with a toxic payload. Tarveda is prepping its first IND now, with an eye to jumping into the clinic later this year with its first therapy.
	5.3 Traitements - FDA, EMA,...
2016: The Year of Diversity in Clinical Trials [FDA Voice] Increasing diversity in clinical trials is a priority for FDA. To that end, in 2016, the Agency is planning a variety of activities to push for greater inclusion, including more minority participation.
	5.4 Traitements - Economie
Experts: High Drug Price Trend Has “Infected” Generics [ASH] An article published online today in Blood, the Journal of the American Society of Hematology (ASH), suggests that pharmaceutical companies use several strategies to keep affordable generic drugs from the market, illustrating an emerging trend that authors say is becoming as harmful to consumers as high-cost brand-name drugs.
	6.10 Politiques
The medical education of Joe Biden [STAT] Even if Biden can encourage more collaboration, the ultimate goal of that effort has been hard for Biden and his advisers to define. The vice president last week expressed some regret over using the word “moonshot,” a term that raises public expectations.
The Health Care Delusion Hillary And Trump Share [Forbes] A market that lowers the price of medicine could well mean some people won’t get the medicine they need. That’s why fixing drug pricing is never going to be as easy as politicians make it sound.
	6.6 Publications
Proposal for data sharing is 'a remarkable turning point,' says Yale's Krumholz [STAT] When I first got into this issue, I wondered whether pharmaceutical companies were the chief offender, but I think it’s the academics.